Production (Stage)
MoonLake Immunotherapeutics
MLTX
$46.88
-$1.95-3.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -39.94M | -45.60M | -35.39M | -24.27M | -13.67M |
| Total Depreciation and Amortization | 378.00K | 1.30M | 32.50K | 28.10K | 328.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.80M | -269.70K | 1.80M | 1.67M | 1.24M |
| Change in Net Operating Assets | -369.00K | -3.90M | 8.28M | -5.32M | -2.85M |
| Cash from Operations | -38.14M | -48.47M | -25.27M | -27.89M | -14.95M |
| Capital Expenditure | -35.00K | -175.60K | -132.20K | 0.00 | -212.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 56.28M | -147.16M | 58.41M | -87.74M | -28.59M |
| Cash from Investing | 56.25M | -147.33M | 58.28M | -87.74M | -28.80M |
| Total Debt Issued | 73.02M | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 100.00K | 150.70K | 91.30K | 0.00 | 52.54M |
| Repurchase of Common Stock | -- | 0.00 | 0.00 | 0.00 | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 91.80K | 0.00 | -1.56M |
| Cash from Financing | 73.12M | 150.70K | 183.10K | 0.00 | 50.98M |
| Foreign Exchange rate Adjustments | -88.00K | 423.80K | -325.40K | -16.90K | 46.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 91.14M | -195.23M | 32.87M | -115.65M | 7.27M |